TY - JOUR
T1 - Prognostic value of Morise clinical score, calcium score and computed tomography coronary angiography in patients with suspected or known coronary artery disease
AU - Maffei, E
AU - Seitun, S
AU - Palumbo, AA
AU - Martini, C
AU - Emiliano, E
AU - Cuttone, A
AU - Aldrovandi, A
AU - Malago, R
AU - la Grutta, L (La)
AU - Midiri, M
AU - Tedeschi, C
AU - De Rosa, R
AU - Catalano, O
AU - Weustink, A.C.
AU - Mollet, Nico
AU - Cademartiri, F.
PY - 2011
Y1 - 2011
N2 - Our aim was to determine the prognostic value of computed tomography coronary angiography (CTCA), coronary artery calcium scoring (CACS) and Morise clinical score in patients with known or suspected coronary artery disease (CAD). A total of 722 patients (480 men; 62.7 +/- 10.9 years) who were referred for further cardiac evaluation underwent CACS and contrast-enhanced CTCA to evaluate the presence and severity of CAD. Of these, 511 (71%) patients were without previous history of CAD. Patients were stratified according to the Morise clinical score (low, intermediate, high), to CACS (0-10, 11-100, 101-400, 401-1,000, > 1,000) and to CTCA (absence of CAD, nonsignificant CAD, obstructive CAD). Patients were followed up for the occurrence of major events: cardiac death, nonfatal myocardial infarction, unstable angina and revascularisation. Significant CAD (> 50% luminal narrowing) was detected in 260 (36%) patients; nonsignificant CAD (< 50% luminal narrowing) in 250 (35%) and absence of CAD in 212 (29%). During a mean follow-up of 20 +/- 4 months, 116 events (21 hard) occurred. In patients with normal coronary arteries on CTCA, the major event rate was 0% vs. 1.7% in patients with nonsignificant CAD and 7.3% in patients with significant CAD (p < 0.0001). Three hard events (14%) occurred in patients with CACSa parts per thousand currency sign100 and two (9.5%) in patients with intermediate Morise score; one revascularisation was observed in a patient with low Morise score. At multivariate analysis, diabetes, obstructive CAD and CACS > 1,000 were significant predictors of events (p < 0.05). An excellent prognosis was noted in patients with a normal CTCA (0% event rate). CACS a parts per thousand currency sign100 and low-intermediate Morise score did not exclude the possibility of events at follow-up.
AB - Our aim was to determine the prognostic value of computed tomography coronary angiography (CTCA), coronary artery calcium scoring (CACS) and Morise clinical score in patients with known or suspected coronary artery disease (CAD). A total of 722 patients (480 men; 62.7 +/- 10.9 years) who were referred for further cardiac evaluation underwent CACS and contrast-enhanced CTCA to evaluate the presence and severity of CAD. Of these, 511 (71%) patients were without previous history of CAD. Patients were stratified according to the Morise clinical score (low, intermediate, high), to CACS (0-10, 11-100, 101-400, 401-1,000, > 1,000) and to CTCA (absence of CAD, nonsignificant CAD, obstructive CAD). Patients were followed up for the occurrence of major events: cardiac death, nonfatal myocardial infarction, unstable angina and revascularisation. Significant CAD (> 50% luminal narrowing) was detected in 260 (36%) patients; nonsignificant CAD (< 50% luminal narrowing) in 250 (35%) and absence of CAD in 212 (29%). During a mean follow-up of 20 +/- 4 months, 116 events (21 hard) occurred. In patients with normal coronary arteries on CTCA, the major event rate was 0% vs. 1.7% in patients with nonsignificant CAD and 7.3% in patients with significant CAD (p < 0.0001). Three hard events (14%) occurred in patients with CACSa parts per thousand currency sign100 and two (9.5%) in patients with intermediate Morise score; one revascularisation was observed in a patient with low Morise score. At multivariate analysis, diabetes, obstructive CAD and CACS > 1,000 were significant predictors of events (p < 0.05). An excellent prognosis was noted in patients with a normal CTCA (0% event rate). CACS a parts per thousand currency sign100 and low-intermediate Morise score did not exclude the possibility of events at follow-up.
U2 - 10.1007/s11547-011-0721-6
DO - 10.1007/s11547-011-0721-6
M3 - Article
VL - 116
SP - 1188
EP - 1202
JO - Radiologia Medica
JF - Radiologia Medica
SN - 0033-8362
IS - 8
ER -